Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

11289	Companies
250837	Keywords
179642	Articles
136677	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/15/2025 at 07:00, 1 year 3 months ago

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
Biophytis partners with Lynx Analytics to accelerate drug discovery for sarcopenia through AI collaboration. The partnership aims to develop small molecule drugs for muscle preservation and regeneration

Biophytis Drug Discovery AI Sarcopenia Lynx Analytics
BRIEF

published on 07/11/2025 at 08:19, 1 year 3 months ago

Biophytis Reports 2024 Financial Results and Strategy for 2025

Drug Discovery Partnerships Biophytis Financials 2025 Strategic Plans Phase 2 And Phase 3 Trials
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 1 year 3 months ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
BRIEF

published on 07/08/2025 at 07:05, 1 year 3 months ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 1 year 3 months ago

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Biophytis SA announces participation in ARC 2025 to present results of BIO101 in sarcopenia at the World Aging & Rejuvenation Conference, aiming to strengthen scientific visibility and expand in the longevity market

Sarcopenia Biophytis SA BIO101 Longevity Market ARC 2025
BRIEF

published on 07/07/2025 at 07:05, 1 year 3 months ago

Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis BIO101 Muscle Preservation GLP-1 Therapies Obesity Market
REGULATED PRESS RELEASE

published on 07/07/2025 at 07:00, 1 year 3 months ago

Obesity: Biophytis Charts Its Course Toward a Booming Market
Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market

BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA
BRIEF

published on 07/03/2025 at 07:05, 1 year 4 months ago

Biophytis Showcases Innovations at BIO International 2025

Biophytis Precision Medicine Longevity Sarcopenia Obesity Therapy
REGULATED PRESS RELEASE

published on 07/03/2025 at 07:00, 1 year 4 months ago

Biophythis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025
Biophytis highlights innovations in obesity, muscle health, and longevity at BIO International 2025, showcasing therapies targeting key health challenges. Strategic partnerships post-conference aim to accelerate therapies' global impact

Innovations Longevity Obesity Muscle Health Biophy(s
BRIEF

published on 06/30/2025 at 22:35, 1 year 4 months ago

Biophytis Delays Publication of 2024 Annual Financial Statements

Biophytis Biotechnology Drug Development Annual Accounts Financial Delay

Accesswire

Published on 11/05/2026 at 23:20, 1 hour 1 minute ago

Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Published on 11/05/2026 at 22:05, 2 hours 16 minutes ago

Innodata Reports Record Third Quarter 2026 Results
Published on 11/05/2026 at 22:01, 2 hours 20 minutes ago

Unusual Machines Third Quarter 2026 Shareholder Letter
Published on 11/05/2026 at 15:20, 9 hours 1 minute ago

MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 9 hours 50 minutes ago

First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile

View all ACCESSWIRE

EQS Group

Published on 11/06/2026 at 00:05, 16 minutes ago

RBI: Announcement of the result of the voluntary public tender offer for all Addiko shares following expiration of the grace period
Published on 11/05/2026 at 22:05, 2 hours 16 minutes ago

Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
Published on 11/05/2026 at 20:38, 3 hours 43 minutes ago

freenet uses funds from Ceconomy sale for waipu.tv acquisition and share buyback
Published on 11/05/2026 at 20:37, 3 hours 44 minutes ago

EQS-Adhoc: freenet AG decides on share buyback programme for up to EUR 75 million
Published on 11/05/2026 at 19:45, 4 hours 35 minutes ago

Stabilus SE fulfills forecast for fiscal 2026 and adjusts 2030 medium-term targets

Les Echos

Published on 11/05/2026 at 18:21, 6 hours ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:50, 6 hours 31 minutes ago

NRJ GROUP - Financial information Q3 2026
Published on 11/05/2026 at 17:45, 6 hours 36 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 6 hours 52 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
Published on 11/05/2026 at 10:16, 14 hours 5 minutes ago

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

View all LES ECHOS COMFI WIRE